These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Current understanding of dystrophin-related muscular dystrophy and therapeutic challenges ahead. Zhou GQ; Xie HQ; Zhang SZ; Yang ZM Chin Med J (Engl); 2006 Aug; 119(16):1381-91. PubMed ID: 16934185 [TBL] [Abstract][Full Text] [Related]
29. Lipofection of a cDNA plasmid containing the dystrophin gene lowers intracellular free calcium and calcium leak channel activity in mdx myotubes. McCarter GC; Denetclaw WF; Reddy P; Steinhardt RA Gene Ther; 1997 May; 4(5):483-7. PubMed ID: 9274726 [TBL] [Abstract][Full Text] [Related]
30. The childhood muscular dystrophies: making order out of chaos. Tsao CY; Mendell JR Semin Neurol; 1999; 19(1):9-23. PubMed ID: 10711985 [TBL] [Abstract][Full Text] [Related]
31. Treatments for muscular dystrophy: increased treatment options for Duchenne and related muscular dystropies. Wells DJ Gene Ther; 2008 Aug; 15(15):1077-8. PubMed ID: 18528429 [No Abstract] [Full Text] [Related]
32. The principles of gene therapy in Duchenne muscular dystrophy. Karpati G; Acsadi G Clin Invest Med; 1994 Oct; 17(5):499-509. PubMed ID: 7867254 [TBL] [Abstract][Full Text] [Related]
33. Myoblast transfer in the treatment of Duchenne's muscular dystrophy. Mendell JR; Kissel JT; Amato AA; King W; Signore L; Prior TW; Sahenk Z; Benson S; McAndrew PE; Rice R N Engl J Med; 1995 Sep; 333(13):832-8. PubMed ID: 7651473 [TBL] [Abstract][Full Text] [Related]
34. [Introduction of rod-deleted dystrophin cDNA, delta DysM3, into mdx skeletal muscle using adenovirus vector]. Yuasa K; Ishii A; Miyagoe Y; Takeda S Nihon Rinsho; 1997 Dec; 55(12):3148-53. PubMed ID: 9436426 [TBL] [Abstract][Full Text] [Related]
35. Developments in gene therapy for muscular dystrophy. Hartigan-O'Connor D; Chamberlain JS Microsc Res Tech; 2000 Feb 1-15; 48(3-4):223-38. PubMed ID: 10679969 [TBL] [Abstract][Full Text] [Related]
36. Gene delivery goes global. Thomas CE Nat Med; 2004 Aug; 10(8):782-3. PubMed ID: 15286775 [No Abstract] [Full Text] [Related]
37. [Development of new therapy on muscular dystrophy]. Takeda S Rinsho Shinkeigaku; 2001 Dec; 41(12):1154-6. PubMed ID: 12235824 [TBL] [Abstract][Full Text] [Related]
38. Gene transfer therapy for heritable disease: cell and expression targeting. Mitani K; Clemens PR; Moseley AB; Caskey CT Philos Trans R Soc Lond B Biol Sci; 1993 Feb; 339(1288):217-24. PubMed ID: 8097051 [TBL] [Abstract][Full Text] [Related]
39. Codon optimization of the microdystrophin gene for Duchene muscular dystrophy gene therapy. Athanasopoulos T; Foster H; Foster K; Dickson G Methods Mol Biol; 2011; 709():21-37. PubMed ID: 21194019 [TBL] [Abstract][Full Text] [Related]
40. Myoblast transfer in DMD: problems in the interpretation of efficiency. Karpati G; Holland P; Worton RG Muscle Nerve; 1992 Oct; 15(10):1209-10. PubMed ID: 1406777 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]